Radovan Vrhovac

List of Publications by Year
in descending order

29	597	933447 10	642732 23
papers	citations	h-index	g-index

29	29	29	1029
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Various approaches for accessing the influence of human leukocyte antigens disparity in haploidentical stem cell transplantation. International Journal of Laboratory Hematology, 2022, , .	1.3	0
2	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). American Journal of Hematology, 2021, 96, 69-79.	4.1	40
3	The Impact of Achieving Complete Remission Prior to Allogeneic Stem Cell Transplantation on Progression-Free Survival in Hodgkin Lymphoma. Clinical Hematology International, 2021, 3, 116.	1.7	1
4	Febrile reaction after hematopoietic stem cell infusion is more frequent if no steroid premedicaton is given which results in more frequent use of antibiotics in early post-transplant phase. Infektoloski Glasnik, 2021, 40, 91-96.	0.2	0
5	Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia, 2021, 35, 3551-3560.	7.2	40
6	Significant Associations of IgG Glycan Structures With Chronic Graft-Versus-Host Disease Manifestations: Results of the Cross-Sectional NIH Cohort Study. Frontiers in Immunology, 2021, 12, 633214.	4.8	1
7	The MHC gamma block matching: Impact on unrelated hematopoietic stem cell transplantation outcome. Human Immunology, 2020, 81, 12-17.	2.4	2
8	Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft-versus-host disease. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2967-2978.	2.5	5
9	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematology,the, 2020, 7, e157-e167.	4.6	319
10	Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Longâ€term follow up of a phase <scp>III</scp> study. American Journal of Hematology, 2020, 95, 749-758.	4.1	12
11	Quantitative polymerase chain reaction technology in chimerism monitoring after hematopoietic stem cell transplantation: One center experience. Hla, 2019, 94, 16-20.	0.6	2
12	Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia ChromosomeÂNegative Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 53-63.	0.4	24
13	Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype. Haematologica, 2019, 104, 1168-1175.	3.5	12
14	Outcome of Patients with Hodgkin Lymphoma Treated with Brentuximab Vedotin for Relapse after Autologous Stem Cell Transplant: A Retrospective Analysis of the LWP-EBMT. Blood, 2019, 134, 4018-4018.	1.4	2
15	Autologous blood as a source of platelet gel for the effective and safe treatment of oral chronic graftâ€versusâ€host disease. Transfusion, 2018, 58, 1494-1499.	1.6	10
16	Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017. Acta Clinica Croatica, 2018, 57, 190-215.	0.2	8
17	Comparative Analysis of Biological and Functional Properties of Bone Marrow Mesenchymal Stromal Cells Expanded in Media with Different Platelet Lysate Content. Cells Tissues Organs, 2018, 205, 226-239.	2.3	4
18	Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15â€“60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials. Annals of Hematology, 2018, 97, 1785-1795.	1.8	4

#	Article	IF	Citations
19	Gut Colonization by Multidrug-Resistant Gram-Negative Bacteria Is an Independent Risk Factor for Development of Intestinal Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 1221-1222.	2.0	5
20	HLA-DPB1 matching in unrelated hematopoietic stem cell transplantation program contributes to a higher incidence of disease relapse. Human Immunology, 2017, 78, 665-671.	2.4	10
21	Anthropometric and Laboratory Variables Related to Weight Lossâ€"Comparison of Heart Failure Patients with Tumor Patients and Control Population. Frontiers in Nutrition, 2017, 4, 18.	3.7	0
22	Myasthenia Gravis Associated with Thymoma and Aplastic Anemia: Case Report. Acta Clinica Croatica, 2017, 56, 817-820.	0.2	1
23	Chronic graft-vs-host disease in 2016: a major challenge and an opportunity. Croatian Medical Journal, 2016, 57, 1-3.	0.7	3
24	Joint and fascial chronic graft-vs-host disease: correlations with clinical and laboratory parameters. Croatian Medical Journal, 2016, 57, 266-275.	0.7	7
25	Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1615-1622.	2.4	6
26	Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials. Blood, 2016, 128, 2847-2847.	1.4	0
27	Implementation of NIH Criteria for Standardization of Chronic Graft-Versus-Host Disease in Croatia: Two-Year Experience. Blood, 2015, 126, 5580-5580.	1.4	0
28	Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Therapeutics and Clinical Risk Management, 2012, 8, 95.	2.0	38
29	Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncology, 2011, 7, 1035-1043.	2.4	41